---
date: "2024-01-13 07:34:42" # 2021-07-14
title: "Baxter International (NYSE: BAX) Receives Downgrade to Hold by StockNews.com"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/BAX' target='_blank'>BAX</a>, <a href='https://finance.yahoo.com/quote/BK' target='_blank'>BK</a>, <a href='https://finance.yahoo.com/quote/IPXAF' target='_blank'>IPXAF</a> 

source: <a href='https://www.defenseworld.net/2024/01/13/baxter-international-nysebax-downgraded-by-stocknews-com-to-hold.html' target='_blank'>Stocknews.com</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| BAX | positively | The downgrade from a "buy" to a "hold" rating by StockNews.com suggests that Baxter International may face challenges in the near term, potentially impacting the stock price positively due to lowered expectations. |
| BK | positively | Baxter International's downgrade may indicate a potential slowdown in the medical instruments industry, which could lead investors to seek alternative investment options such as banking stocks like BK. |
| IPXAF | positively | It is not mentioned how the ticker IPXAF will be affected positively in the article. |



#### our strategies and bots using these tickers

None so far...

## summary

# Baxter International Downgraded by StockNews.com to "Hold"

Baxter International (NYSE:BAX) has been downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a report released on Thursday. This downgrade comes after the company has been the topic of several other research reports.

JPMorgan Chase & Co. decreased their price target on shares of Baxter International from $49.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, October 31st. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Baxter International from $35.00 to $50.00 and gave the company a "hold" rating in a research note on Tuesday, October 24th. Morgan Stanley decreased their target price on shares of Baxter International from $45.00 to $39.00 and set an "equal weight" rating for the company in a research note on Monday, December 4th. Finally, Citigroup decreased their target price on shares of Baxter International from $45.00 to $41.00 in a research note on Monday, October 2nd.

Currently, seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Baxter International presently has an average rating of "Hold" and an average target price of $46.09.

Baxter International opened at $40.00 on Thursday. The company has a twelve month low of $31.01 and a twelve month high of $50.21. The stock has a market cap of $20.29 billion, a PE ratio of 7.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.64. The business's 50 day moving average is $37.09 and its 200-day moving average is $39.22. The company has a current ratio of 1.94, a quick ratio of 1.48, and a debt-to-equity ratio of 1.72.

Baxter International last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. Baxter International had a return on equity of 21.38% and a net margin of 17.34%. The firm had revenue of $3.71 billion for the quarter, compared to analysts' expectations of $3.69 billion. On average, analysts predict that Baxter International will post 2.6 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in shares of Baxter International by 69.0% during the third quarter. Bank of New York Mellon Corp now owns 6,491,343 shares of the medical instruments supplier's stock worth $244,983,000 after purchasing an additional 2,650,959 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Baxter International by 9.0% during the second quarter. Impax Asset Management Group plc now owns 838,200 shares of the medical instruments supplier's stock worth $38,188,000 after purchasing an additional 69,105 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Baxter International by 18.5% during the second quarter. Geode Capital Management LLC now owns 10,629,326 shares of the medical instruments supplier's stock worth $482,991,000 after purchasing an additional 1,658,160 shares in the last quarter. Symmetry Partners LLC acquired a new position in shares of Baxter International during the second quarter worth approximately $314,000. Finally, Handelsbanken Fonder AB lifted its position in shares of Baxter International by 6.0% during the third quarter. Handelsbanken Fonder AB now owns 201,819 shares of the medical instruments supplier's stock worth $7,617,000 after purchasing an additional 11,456 shares in the last quarter. 85.47% of the stock is owned by institutional investors.

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, along with additional dialysis therapies and services, intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices. They also provide premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services. Other offerings include parenteral nutrition therapies and related products, biological products, and medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention. Baxter International also focuses on continuous renal replacement therapies and other organ support therapies in the intensive care unit.

Disclaimer: This article is for informational purposes only and should not be taken as investment advice. Always conduct thorough research and consult with a professional financial advisor before making any investment decisions.